You have built something real. A platform, a device, a therapy, or a diagnostic tool that has cleared its first regulatory hurdle and is moving toward clinical validation or commercial launch. The science works. The team is in place. The next conversation is with investors, a distribution partner, or a research institution that wants to run your protocol.
Then the term sheet arrives, or the partnership agreement draft lands, and somewhere in the conditions precedent or the representations and warranties, there is a requirement to hold professional indemnity insurance, product liability insurance, and directors and officers liability insurance at specified limits, with certificates of currency provided before closing.
For many life sciences founders in Singapore, this is the first time insurance has appeared as a substantive business question rather than an administrative afterthought. The problem is that the insurance programme most companies have at that point, if they have one at all, was not designed for where the business now sits.
This post is a practical guide to what a Singapore life sciences company's insurance programme should look like at each stage of development, what investors and partners typically require, and where the gaps in a standard commercial programme are most likely to appear.
Why life sciences companies carry a distinct insurance profile
Most commercial insurance products are designed for businesses that sit clearly in one of three categories: professional services firms that give advice, manufacturers that make physical products, or technology companies that develop software. The liability that arises from each is well-understood and the policy wordings have been refined over decades to address it.
A life sciences company does not sit cleanly in any of these categories. A Singapore MedTech firm developing a diagnostic device may simultaneously be providing scientific consulting services to research partners, manufacturing a physical device that will be used on human patients, holding clinical trial data that is personal health information under the PDPA, and making representations to investors about the company's regulatory pipeline. Each of these activities creates a different category of liability.
The consequence is that a life sciences company which arranges standard commercial cover, a business owner's package or a standard SME policy, may hold a set of policies that collectively address almost none of its material risk. Standard product liability policies exclude investigational products. Standard professional indemnity wordings may exclude bodily injury. Standard cyber policies may not address the specific data sensitivity of clinical research. And a standard D&O policy written for an SME may not carry the limits that institutional investors require.
Arranging insurance for a life sciences company is not a matter of finding the cheapest version of a standard product. It is a matter of identifying the specific liability profile of the business and confirming that the programme addresses it.
The five cover lines that matter
Professional indemnity and technology errors and omissions
Professional indemnity (PI) insurance** **covers claims made against the company for acts, errors, or omissions in the provision of professional services. For a life sciences company, the professional services dimension extends well beyond conventional consulting: it includes contract research services, data analysis and reporting, regulatory advisory work, laboratory testing, and for health technology firms, the outputs of software platforms used in clinical or commercial decision-making.
For a health technology company whose platform produces clinical recommendations, the liability that arises when a recommendation turns out to be wrong is a technology errors and omissions claim. The platform did not give advice in the conventional sense, but its output was used as the basis for a clinical or commercial decision, and when that decision causes harm, the claim flows to the platform provider. Standard PI wordings may not address this, and a technology E&O endorsement or specialist wording is needed.
For CROs providing contract research services to pharmaceutical or biotech clients, PI is the primary liability cover. An error in trial design, a mistake in data management, or a flaw in a regulatory submission that causes a client's programme to fail generates a PI claim that can be significant relative to the value of the original service contract.
PI policies are written on a claims-made basis. The policy that responds to a claim is the one in force when the claim is made, not the one in force when the work was done. The retroactive date on the policy determines how far back the coverage window extends. For a CRO or health tech firm that has been providing services for several years, confirming that the retroactive date reflects the full period of service delivery is a practical step worth taking at each renewal.
You can read more about our professional indemnity cover on the products page.
Product liability
Product liability insurance covers the company's legal liability to third parties for bodily injury or property damage caused by a product it manufactures, distributes, or sells. For a medical device company, a pharmaceutical distributor, or a nutraceutical brand, product liability is a primary insurance requirement.
In Singapore, medical devices sold or distributed commercially must be registered with the Health Sciences Authority (HSA) under the Health Products Act 2007. HSA registration confirms that the device meets the applicable safety and performance standards. But registration is a regulatory requirement, not an insurance product. The liability that arises when a registered device causes harm to a patient is a civil liability matter that HSA registration does not address.
This is a gap that many MedTech founders do not appreciate until they see it in a distribution agreement. A distributor that takes on a medical device for the Singapore market will typically require the manufacturer or importer to hold product liability insurance at a specified minimum limit as a condition of the distribution arrangement. The product may be HSA-registered. The distributor wants evidence of insurance cover, because HSA registration tells them the product met the regulator's standards at the point of approval, not that it will never cause harm to a patient.
For a medical device company whose product is implantable, involves energy delivery, or interfaces with a patient's physiology in a way that carries meaningful clinical risk, the product liability limit needs to reflect the realistic scale of a worst-case claim from patient harm, not the minimum that satisfies the distribution agreement.
Product liability cover needs to be in place before the first product is supplied or distributed commercially. Arranging it after a claim has arisen, or after a distribution partner has requested it, is at best a late start and at worst not possible if a claim has already been notified.
You can read more about our product liability cover on the products page.
Directors and Officers insurance
Directors and Officers (D&O) insurance covers the personal legal costs of directors and officers where claims are made against them in their individual capacity as decision-makers. For a life sciences company backed by institutional investors, D&O is not optional. It is required.
The typical investor requirement appears in the conditions precedent of the term sheet: the company must have in place a D&O policy at a specified minimum limit before the funding round closes. This requirement exists because institutional investors, once they hold a board seat or a significant equity stake, have a direct financial interest in ensuring that the individuals making decisions about the company are not exposed to personal financial ruin from a claim that arises from those decisions. A claim against a director that results in a personal financial judgment against them, without D&O cover in place, creates a governance and management continuity problem that the investor has a direct interest in avoiding.
Beyond the investor requirement, D&O cover addresses claims that arise from the specific governance environment of a venture-backed life sciences company. A regulatory investigation by HSA or MAS. A claim from an early investor alleging that the company's representations about the pipeline were misleading. A dispute between co-founders that results in a claim by one director against another for breach of fiduciary duty. A claim by a clinical partner alleging that the company's board made decisions that caused the partner material harm. Each of these is a D&O claim scenario, and each is more likely to arise in a venture-backed life sciences company than in a conventional SME.
The D&O limit required by investors varies. Seed and early-stage rounds typically require a minimum of S$1 million to S$2 million. Series A and above typically require S$5 million or more. Confirming the limit requirement from the term sheet before arranging the policy, rather than arranging a policy and then discovering the limit is inadequate, is the right sequencing.
You can read more about our D&O cover on the products page.
Cyber insurance
A life sciences company holds data that is both legally protected and commercially sensitive in ways that few other businesses experience simultaneously. Clinical trial data from human participants is personal health data subject to Singapore's Personal Data Protection Act 2012. Where trial participants are enrolled in other jurisdictions, equivalent data protection legislation in those jurisdictions applies. Proprietary research data represents years of scientific work and potentially significant commercial value. Regulatory submissions contain information that would be of interest to competitors.
A data breach affecting a life sciences company creates consequences that extend beyond the standard PDPA notification obligation. A breach affecting trial participant data may require notification to regulatory authorities in multiple jurisdictions. A breach exposing proprietary research data may affect the company's patent strategy or competitive position. A breach that becomes public may affect investor confidence and ongoing partnership discussions.
Cyber insurance covers the direct costs of responding to and managing a data breach or cyber incident: forensic investigation, legal advice on notification obligations, the cost of notifying affected individuals, and business interruption during the response period. For a life sciences company with international trial sites, confirming that the cyber policy covers notification obligations in each relevant jurisdiction is a practical step at inception.
You can read more about our cyber insurance on the products page.
Clinical trials insurance
For life sciences companies conducting clinical trials involving human subjects in Singapore, clinical trials insurance is a regulatory requirement. The Health Sciences Authority requires sponsors to hold appropriate clinical trial insurance, including no-fault compensation for trial participants, before the first participant is enrolled, according to HSA's published guidance under the Health Products Act.
No-fault compensation is the specific feature that distinguishes clinical trials insurance from standard liability insurance. A trial participant who suffers an adverse event as a result of the investigational product may be entitled to compensation even where no negligence on the sponsor's part can be established. This reflects the ethical obligation to individuals who voluntarily take on risk in the advancement of scientific knowledge. Standard liability insurance requires fault to be established before a claim is paid.
For trials conducted across multiple sites in different jurisdictions, each jurisdiction may have its own compulsory insurance requirement and minimum coverage standard. Coordinating a master programme that satisfies the local compulsory requirements in each jurisdiction, while avoiding duplication and ensuring no gaps between policies, requires specialist structuring that is best addressed at the design stage of the trial, not at the point of regulatory submission.
What investors and commercial partners require
The insurance requirements in term sheets and commercial partnership agreements are not boilerplate. They reflect a considered risk management position by the party requesting them, and understanding what each requirement is protecting against is useful context for the founder reviewing the agreement.
PI insurance is required by commercial partners who are relying on the life sciences company's scientific outputs, data, or platform. A CRO client who relies on trial data to support a regulatory submission wants evidence that the CRO holds PI cover, because if the data turns out to be flawed, the client has a recoverable claim against the CRO's policy rather than an unsecured claim against the CRO's balance sheet.
Product liability insurance is required by distributors and commercial partners who will be handling or marketing the company's product in the market. The distributor is a party in the supply chain, and a product that causes harm generates a claim that flows through the supply chain. The distributor wants evidence that the manufacturer holds adequate product liability cover so that a claim from a downstream patient or customer is addressed by the manufacturer's policy rather than becoming a dispute between the distributor and an uninsured counterparty.
D&O insurance is required by institutional investors as a condition of closing because it protects the governance continuity of the business they are investing in. An uninsured director who faces a personal claim may be distracted from running the business, or may exit, during a period when the investor needs management stability.
When reviewing contract language, three points are worth checking specifically. First, the minimum limit specified for each cover line, and whether the company's current policy meets it. Second, the requirement to add the counterparty as an additional insured on specific policies, which some distributors and partners require. Third, the notice requirement for policy changes or cancellations, which some agreements require to be notified to the counterparty within a specified number of days.
What to review at each growth stage
Pre-revenue and research stage
At this stage the primary insurance priorities are D&O to protect the founding team, PI or technology E&O if the company is providing any services to external parties, and basic cyber cover for research data. Product liability is not yet relevant if no product has been commercialised. Clinical trials insurance becomes relevant at the point of moving into human studies.
Commercial launch
When the first product is distributed commercially or the first service contract is signed with an external client, product liability and PI become primary requirements. The territorial scope of the product liability policy needs to match the markets where the product is being distributed. If distribution agreements require the company to hold cover at specified limits, confirming those limits are in place before signing is the right sequencing.
Series A and above
At this stage the D&O limit is typically the most pressing insurance question. Institutional investors will specify their requirements in the term sheet. The PI and product liability programmes should be reviewed to confirm they reflect the full scope of the company's current activities, not the activities at the time the policies were originally arranged. As the company's pipeline and commercial activities expand, the scope of the insurance programme needs to expand with it.
Regional expansion
When the company begins distributing products, running trials, or providing services in markets outside Singapore, the territorial scope of every policy in the programme needs to be confirmed. A PI policy arranged for Singapore operations may not automatically extend to services provided in Malaysia, Indonesia, or other ASEAN markets. A product liability policy may exclude specific jurisdictions. A cyber policy may not cover notification obligations under data protection regimes outside Singapore. Territorial scope is a policy wording question that needs to be confirmed with the insurer at the point of expansion, not assumed to follow automatically.
You can read more about how life sciences insurance is structured in our post on Life Sciences Insurance in Singapore and about clinical trials insurance specifically in our post on Biotech Insurance in Singapore.
If you are a founder or senior executive at a Singapore life sciences company and would like to understand how your current insurance programme sits against your stage of development, your investor requirements, or your upcoming commercial partnerships, we would be glad to work through it with you.
This article provides general information only. It is not insurance or legal advice. HSA medical device registration requirements sourced from the Health Sciences Authority under the Health Products Act 2007. HSA clinical trial insurance requirements sourced from HSA published guidance. D&O limit expectations described reflect general market practice for venture-backed life sciences companies in Singapore and may vary by investor and transaction. Founders and directors should seek qualified legal advice on their specific contractual obligations. Policy availability, terms, conditions, and exclusions vary by insurer and product, and cover is subject to the full policy wording. Please contact TZY CO for advice on your specific situation.